Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Research and Development (R&D)

PhRMA Publishes 2017 Biopharmaceutical Industry Resources; Member Companies Spent $65.5 Billion on R&D in 2016

PhRMA’s 2017 “Chart Pack”

Washington, DC, September 14, 2017 — Did you know that Pharmaceutical Research and Manufacturers of America (PhRMA) member companies invested $65.5 billion in research and development (R&D) in 2016?

Or that combined spending on brand medicines, generics and the supply chain account for 14 percent of total national health spending, with brands accounting for just half of this (7 percent)?

Or that the United States accounts for two thirds of the world’s venture capital investments in high-growth biopharmaceutical startups?

These are but a few of the facts that can be found in PhRMA’s 2017 Biopharmaceutical Research Industry Profile and the 152-page industry chart pack, Biopharmaceuticals in Perspective, which were released July 20.
Continue reading

Trump Administration’s R&D Memo Directs Agencies to Emphasizes Basic Science

President Donald Trump

Westerville, OH, August 28, 2017 ― The State Science & Technology Institute (SSTI) blogs that the White House Office of Management and Budget (OMB) on August 17 released a memorandum on research and development (R&D) priorities that directs agencies to prioritize basic science and lower costs in their FY 2019 budget requests.

R&D investments should be made in military superiority, security, prosperity, energy dominance and health.

The memo repeatedly encourages officials to identify, and divest of, research areas where industry is ready to make their own investments toward commercial development. Continue reading

Biopharmaceutical Companies Unveil Latest GoBOLDLY TV Ad Showcasing ‘New World’ of Medicine

Washington, DC, May 17, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on May 15 unveiled its latest advertisement as part of its groundbreaking GOBOLDLY™ campaign, titled “New World, “featuring some of the most extraordinary breakthroughs in science being discovered by biopharmaceutical researchers.

“Biopharmaceutical researchers are driving unimaginable innovation in science, which is revolutionizing how the most complex diseases are treated,” said Stephen J. Ubl, president and chief executive officer of PhRMA.

“We truly are in a new world of medicine and on the verge of something even greater and more impactful. This promises a future with endless potential of scientific advances.” Continue reading

AAAS Applauds Congress for Protecting Fiscal 2017 R&D Spending

Washington, DC, May 17, 2017 — Anne Q. Hoy reports that the American Association for the Advancement of Science (AAAS) applauded congressional leaders for their bipartisan support in backing fiscal 2017 funding for research and development programs, according to a letter AAAS sent to House and Senate leaders on May 9.

“We commend Congress and the White House for working together to prevent a government shutdown and finalizing appropriations for fiscal year 2017,” said Rush Holt, AAAS CEO and executive publisher of the Science family of journals, in the letter sent to House Speaker Paul Ryan (R-Wis.), House Minority Leader Nancy Pelosi (D-Calif.), Senate Majority Leader Mitch McConnell (R-Ky.) and Senate Minority Leader Charles E. Schumer (D-N.Y.). Continue reading

With an Emphasis on R&D, PhRMA Board of Directors Establishes New Membership Criteria

Washington, DC, May 11, 2017 — Demonstrating its commitment to representing research- based biopharmaceutical companies, the board of directors for the Pharmaceutical Research and Manufacturers of America (PhRMA) on May 9 approved new criteria for membership.

Biopharmaceutical companies will now have to meet new research and development (R&D) requirements in order to be eligible to join PhRMA.

In making the announcement, Joaquin Duato, PhRMA board chairman and worldwide chairman, pharmaceuticals, Johnson & Johnson, said, “By putting in place new membership criteria, the board is sending a clear message that being a member of PhRMA means being committed to doing the time-intensive, scientifically sound research it takes to bring bold new advances in treatments and cures to patients.” Continue reading